CompletedPhase 3

Rifaximin for Prevention of Travellers' Diarrhea

Mexico210 participantsStarted 2005-06

Plain-language summary

The purpose of this study is to determine if 600 mg of rifaximin, taken once a day for 14 days by healthy subjects, is safe and effective for the prevention of travellers' diarrhea compared to placebo.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. travelling to Mexico within 72 hours of enrollment
✓. read and understand English
✓. in good health

Exclusion criteria

✕. acute diarrhea within previous 7 days
✕. taken FQs (any drug in this class), macrolide, azalide, or trimethoprim-sulfamethoxazole within 7 days or enrollment or anytime during study.
✕. taken antidiarrheal medication within 24 hours of enrollment or anytime during study.

What they're measuring

Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment

Timeframe: 14 days

Trial details

NCT IDNCT00742469

SponsorBausch Health Americas, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2005-09

Results submitted2017-12-08

View on ClinicalTrials.gov More Diarrhea trials